Premium
Testing two scales to measure sleep disturbance in people with eczema
Publication year - 2020
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.19514
Subject(s) - sleep disorder , sleep (system call) , disturbance (geology) , medicine , atopic dermatitis , audiology , physical therapy , clinical psychology , psychiatry , dermatology , insomnia , paleontology , computer science , biology , operating system
People with atopic dermatitis (AD) often find it hard to sleep, and these sleep disturbances are caused by itch, skin pain and other AD symptoms. Sleep disturbance is an important domain to be monitored in clinics, and in trials, for example when new treatments are tested or different treatments compared. Different measures are used to asses someone’s sleep disturbance, but there is limited data to support the validity of any of these measures of sleep disturbance in AD patients. In this study, we set out to determine the measurement properties of the Patient‐Reported Outcomes Information System (PROMIS©) Sleep Disturbance (SD), and Sleep‐Related Impairment (SRI) in adults with AD. We evaluated a group of 420 adults with AD who were patients at an academic medical center. We measured AD severity using multiple self‐assessments and clinician‐assessments. We used the PROMIS SD and SRI scales and other measures to assess their sleep. PROMIS SD and SRI showed good concurrent (i.e. correlated well with each other), convergent (i.e. correlated well with other measures of AD severity), discriminant (i.e. scores were able to predict more severe AD and sleep disturbance) and cross‐cultural validity (i.e. items performed similarly across different patient subsets). PROMIS SD and SRI also showed good measurement properties with respect to feasibility for use in clinical practice (i.e. in clinics), and with no floor or ceiling effects (when most of your respondents score near the bottom or top). This, along with other findings outlined in the full study, suggests that PROMIS SD and SRI have good validity for assessing sleep in adults with AD. We recommend that clinicians screen all AD patients for sleep disturbances. Linked Article: Lei et al. Br J Dermatol 2020; 183: 875–882.